Mineralys Therapeutics (MLYS) Non Operating Income (2022 - 2026)

Mineralys Therapeutics has reported Non Operating Income for 5 years, with the latest figure at $6.0 million in Q1 2026.

• Quarterly Non Operating Income rose 168.02% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (up 51.99% YoY) and the FY2025 annual result came in at $16.0 million, up 9.36% from the prior year.
• Non Operating Income declined to $6.0 million in Q1 2026 per MLYS's latest filing, from $6.0 million in the prior quarter.
• Over five years, Non Operating Income peaked at $6.0 million in Q4 2025 and troughed at $745000.0 in Q3 2022.
• A 5-year average of $3.4 million and a median of $3.5 million in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income surged 371.54% in 2023, then slumped 41.89% in 2025.
• Over 5 years, Non Operating Income stood at $935000.0 in 2022, then surged by 255.19% to $3.3 million in 2023, then retreated by 15.21% to $2.8 million in 2024, then surged by 114.7% to $6.0 million in 2025, then declined by 0.74% to $6.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $6.0 million, $6.0 million, and $4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.